EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

NKG2A–HLA-E and TIM3–galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma

Yuanyu Lin, Wanhua Feng, Yan Li, Yisen Tang, Xiaomei Zhuang, Yingzi Huang, Juping Xie, Kai Liu, Youwen Fan, Yajun Tang, Dong Li, Ziming He und 8 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04479-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yuanyu Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, NK Cell Lectin-Like Receptor Subfamily C, Hepatitis A Virus Cellular Receptor 2, Pancreatic Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China, Shenzhen Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalNK Cell Lectin-Like Receptor Subfamily CHepatitis A Virus Cellular Receptor 2Pancreatic NeoplasmsHistocompatibility Antigens Class IGalectinsHumansHLA-E AntigensSignal TransductionFemaleLymphocytes, Tumor-InfiltratingCell Line, Tumor

Stichwörter der Autor:innen

Ampullary adenocarcinomaImmune checkpointImmunotherapyPancreatic benign tumorPancreatic ductal adenocarcinoma

Substanzen

HLA-E AntigensNK Cell Lectin-Like Receptor Subfamily CLGALS9 protein, humanHepatitis A Virus Cellular Receptor 2HAVCR2 protein, humanHistocompatibility Antigens Class IGalectinsKLRC1 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
  • Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming, Shenzhen, 518107, Guangdong, China.
  • Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
  • Department of Pathology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
  • Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. tangdi@mail.sysu.edu.cn.

Förderung

  • Shenzhen Science and Technology Innovation Program
  • National Natural Science Foundation of China
  • Shenzhen Medical Research Fund
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Lin, Y., Feng, W., Li, Y., Tang, Y., Zhuang, X., Huang, Y., Xie, J., Liu, K., Fan, Y., Tang, Y., Li, D., He, Z., Qiu, Y., Chen, J., Xu, J., Yang, Z., Lan, L., Tang, D., Deng, G., & Zhou, G. (2026). NKG2A–HLA-E and TIM3–galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04479-9

Vancouver

Lin Y, Feng W, Li Y, Tang Y, Zhuang X, Huang Y, et al. NKG2A–HLA-E and TIM3–galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04479-9

BibTeX
@article{Lin2026,
  author = {Lin, Yuanyu and Feng, Wanhua and Li, Yan and Tang, Yisen and Zhuang, Xiaomei and Huang, Yingzi and Xie, Juping and Liu, Kai and Fan, Youwen and Tang, Yajun and Li, Dong and He, Ziming and Qiu, Yuxiong and Chen, Junzong and Xu, Jie and Yang, Zheng and Lan, Linxiang and Tang, Di and Deng, Gang and Zhou, Guoying},
  title = {NKG2A–HLA-E and TIM3–galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04479-9}
}
Kostenlos starten →